Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience
KRAS mutation is an important predictive and prognostic factor for patients receiving anti-EGFR therapy. An expanded KRAS, NRAS, BRAF, PIK3CA mutation analysis provides additional prognostic information, but its role in predicting bevacizumab efficacy is unclear. T he aim of our study was to evaluat...
Uloženo v:
| Vydáno v: | Acta medica Lituanica |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Francês |
| Vydáno: |
Vilniaus Universitetas
2016
|
| Témata: | |
| On-line přístup: | https://www.redalyc.org/articulo.oa?id=694073987006 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|